The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:MDCO
- CUSIP: 58468810
- Web: www.themedicinescompany.com
- Market Cap: $2.82028 billion
- Outstanding Shares: 71,072,000
- 50 Day Moving Avg: $38.46
- 200 Day Moving Avg: $44.43
- 52 Week Range: $30.80 - $55.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.61
- P/E Growth: -0.09
- Annual Revenue: $141.74 million
- Price / Sales: 19.79
- Book Value: $7.26 per share
- Price / Book: 5.44
- EBIDTA: ($306,000,000.00)
- Net Margins: -91.25%
- Return on Equity: -19.09%
- Return on Assets: -7.60%
- Debt-to-Equity Ratio: 0.59%
- Current Ratio: 1.04%
- Quick Ratio: 0.90%
- Average Volume: 1.24 million shs.
- Beta: 0.86
- Short Ratio: 12.43
Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)
What is The Medicines Company's stock symbol?
The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."
How were The Medicines Company's earnings last quarter?
The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings results on Wednesday, April, 26th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.13) by $0.31. The business earned $24.20 million during the quarter, compared to analyst estimates of $37.76 million. The Medicines Company had a negative net margin of 91.25% and a negative return on equity of 19.09%. The company's revenue was down 51.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.03) earnings per share. View The Medicines Company's Earnings History.
Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?
10 brokers have issued 1 year price targets for The Medicines Company's stock. Their predictions range from $43.00 to $65.00. On average, they expect The Medicines Company's share price to reach $54.80 in the next twelve months. View Analyst Ratings for The Medicines Company.
What are analysts saying about The Medicines Company stock?
Here are some recent quotes from research analysts about The Medicines Company stock:
- 1. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)
- 2. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also encouraged by the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the Zacks classified Medical-Biomedical/Genetics industry in last one year. However the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to market is important for future growth and any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/10/2017)
Who are some of The Medicines Company's key competitors?
Some companies that are related to The Medicines Company include Hill-Rom Holdings (HRC), Icon Plc (ICLR), Mednax (MD), Masimo Corporation (MASI), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Taro Pharmaceutical Industries (TARO), Mallinckrodt PLC (MNK), Exact Sciences Corporation (EXAS), Acadia Healthcare Company (ACHC), PAREXEL International Corporation (PRXL), Hikma Pharmaceuticals Plc (HKMPF), Medidata Solutions (MDSO), Alere (ALR), Bio-Techne Corp (TECH), VWR Corporation (VWR), bluebird bio (BLUE) and Integra LifeSciences Holdings Corporation (IART).
Who are The Medicines Company's key executives?
The Medicines Company's management team includes the folowing people:
- Stuart A. Kingsley, President, Chief Operating Officer
- Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director
- William Bernard O'Connor, Chief Financial Officer
- Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer
- Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer
- Stephen M. Rodin J.D., General Counsel, Secretary
- Fredric N. Eshelman, Independent Non-Executive Chairman of the Board
- Paris Panayiotopoulos, Director
- William W. Crouse, Independent Director
- Alexander J. Denner Ph.D., Independent Director
Who owns The Medicines Company stock?
The Medicines Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.21%), Louisiana State Employees Retirement System (0.04%), Aperio Group LLC (0.04%), Whittier Trust Co. (0.04%), State of Alaska Department of Revenue (0.02%) and Capstone Asset Management Co. (0.02%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Glenn Sblendorio, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.
Who sold The Medicines Company stock? Who is selling The Medicines Company stock?
The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co., Nisa Investment Advisors LLC, US Bancorp DE and Bank of Montreal Can. Company insiders that have sold The Medicines Company stock in the last year include Clive Meanwell and William Bernard O'connor. View Insider Buying and Selling for The Medicines Company.
Who bought The Medicines Company stock? Who is buying The Medicines Company stock?
The Medicines Company's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning, State of Alaska Department of Revenue, Aperio Group LLC, Whittier Trust Co. and Louisiana State Employees Retirement System. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.
How do I buy The Medicines Company stock?
Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Medicines Company's stock price today?
MarketBeat Community Rating for The Medicines Company (NASDAQ MDCO)MarketBeat's community ratings are surveys of what our community members think about The Medicines Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of The Medicines Company stock can currently be purchased for approximately $39.47.
Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 8 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$54.80 (38.84% upside)|
Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
(Data available from 7/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/17/2017||Citigroup Inc.||Lower Price Target||Neutral||$59.00 -> $43.00||Medium|
|6/28/2017||Jefferies Group LLC||Reiterated Rating||Buy||$62.00||Low|
|5/23/2017||CIBC||Set Price Target||$50.00||Medium|
|5/22/2017||Oppenheimer Holdings, Inc.||Initiated Coverage||Market Perform||$50.00||Low|
|4/19/2017||Cowen and Company||Boost Price Target||Outperform||$39.00 -> $61.00||Low|
|3/20/2017||HC Wainwright||Reiterated Rating||Buy||$60.00||High|
|3/18/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||High|
|3/1/2017||Royal Bank Of Canada||Reiterated Rating||Buy||N/A|
|1/8/2017||Chardan Capital||Reiterated Rating||Buy||$65.00||N/A|
|11/8/2016||Leerink Swann||Reiterated Rating||Outperform||$53.00 -> $50.00||N/A|
|7/12/2016||Bank of America Corporation||Reiterated Rating||Buy||N/A|
|11/6/2015||Piper Jaffray Companies||Reiterated Rating||Neutral||$28.00 -> $31.00||N/A|
Earnings History for The Medicines Company (NASDAQ:MDCO)Earnings History by Quarter for The Medicines Company (NASDAQ MDCO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/26/2017||Q1 2017||($1.13)||($1.44)||$37.76 million||$24.20 million||View||N/A|
|2/28/2017||Q416||($1.43)||($1.29)||$26.91 million||$25.20 million||View||Listen|
|10/26/2016||Q316||($1.38)||($0.64)||$37.26 million||$37.60 million||View||Listen|
|7/27/2016||Q216||($1.16)||($0.62)||$41.93 million||$54.70 million||View||Listen|
|5/9/2016||Q116||($0.89)||($1.03)||$48.96 million||$50.30 million||View||Listen|
|2/17/2016||Q415||($1.54)||($0.88)||$64.11 million||$67.20 million||View||N/A|
|11/3/2015||Q315||($0.88)||($0.90)||$68.58 million||$72.70 million||View||Listen|
|7/29/2015||Q215||($0.20)||($0.74)||$122.58 million||$90.50 million||View||Listen|
|5/5/2015||Q115||($0.68)||($0.02)||$138.78 million||$126.50 million||View||Listen|
|2/18/2015||Q414||($0.84)||$0.11||$188.55 million||$191.00 million||View||Listen|
|10/22/2014||Q314||($0.10)||$0.10||$188.30 million||$172.40 million||View||Listen|
|7/23/2014||Q214||($0.07)||$0.22||$183.75 million||$183.80 million||View||Listen|
|4/23/2014||Q114||($0.13)||$0.22||$175.60 million||$177.20 million||View||Listen|
|2/19/2014||Q413||$0.11||$0.26||$182.60 million||$185.00 million||View||Listen|
|10/23/2013||Q313||$0.24||$0.47||$173.86 million||$173.45 million||View||Listen|
|7/24/2013||Q2 2013||$0.33||$0.50||$168.70 million||$172.00 million||View||Listen|
|4/24/2013||Q1 2013||($0.26)||$0.31||$152.63 million||$155.80 million||View||Listen|
|2/20/2013||Q4 2012||$0.28||$0.38||$146.09 million||$159.50 million||View||Listen|
Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.10)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/7/2017||William Bernard O'connor||CFO||Sell||25,833||$46.20||$1,193,484.60|| |
|12/8/2016||Christopher T Cox||EVP||Buy||105,500||$33.20||$3,502,600.00|| |
|12/8/2016||Fredric N Eshelman||Director||Buy||621,720||$33.77||$20,995,484.40|| |
|9/21/2016||Clive Meanwell||CEO||Sell||8,623||$40.00||$344,920.00|| |
|9/1/2016||Clive Meanwell||CEO||Sell||1,377||$40.00||$55,080.00|| |
|8/24/2016||Clive Meanwell||CEO||Sell||20,000||$40.00||$800,000.00|| |
|7/11/2016||Hiroaki Shigeta||Director||Sell||3,849||$38.50||$148,186.50|| |
|6/10/2016||Christopher T Cox||EVP||Buy||45,985||$37.90||$1,742,831.50|| |
|6/7/2016||Christopher T Cox||EVP||Buy||53,340||$37.55||$2,002,917.00|| |
|5/24/2016||Melvin K Spigelman||Director||Sell||15,000||$37.00||$555,000.00|| |
|5/16/2016||Clive Meanwell||CEO||Sell||10,000||$35.00||$350,000.00|| |
|5/16/2016||William Crouse||Director||Sell||15,000||$35.15||$527,250.00|| |
|5/13/2016||Elizabeth H S Wyatt||Director||Sell||15,000||$34.07||$511,050.00|| |
|5/12/2016||Fredric N Eshelman||Director||Buy||300,000||$33.68||$10,104,000.00|| |
|3/7/2016||Armin M Kessler||Director||Sell||8,100||$34.82||$282,042.00|| |
|11/13/2015||Robert G. Savage||Director||Sell||5,000||$39.34||$196,700.00|| |
|9/3/2015||Glenn Sblendorio||CFO||Sell||25,000||$42.00||$1,050,000.00|| |
|8/31/2015||Clive Meanwell||CEO||Sell||49,998||$39.36||$1,967,921.28|| |
|8/31/2015||Glenn Sblendorio||CFO||Sell||114,495||$39.75||$4,551,176.25|| |
|8/31/2015||Melvin K. Spigelman||Director||Sell||20,000||$40.50||$810,000.00|| |
|8/31/2015||William Bernard O'connor||SVP||Sell||35,451||$40.00||$1,418,040.00|| |
|7/1/2015||Clive Meanwell||CEO||Sell||16,667||$28.39||$473,176.13|| |
|6/25/2015||Glenn Sblendorio||CFO||Sell||3,305||$32.00||$105,760.00|| |
|6/8/2015||Hiroaki Shigeta||Director||Sell||7,500||$28.99||$217,425.00|| |
|5/20/2015||Robert G Savage||Director||Sell||15,000||$26.78||$401,700.00|| |
|4/16/2015||William Bernard O'connor||SVP||Sell||1,281||$30.00||$38,430.00|| |
|4/1/2015||Clive Meanwell||CEO||Sell||16,667||$27.58||$459,675.86|| |
|3/30/2015||Elizabeth H S Wyatt||Director||Sell||20,000||$28.08||$561,600.00|| |
|3/23/2015||Clive Meanwell||CEO||Sell||16,667||$30.62||$510,343.54|| |
|3/23/2015||Glenn Sblendorio||CFO||Sell||34,773||$30.78||$1,070,312.94|| |
|3/2/2015||William Bernard O'connor||SVP||Sell||2,988||$28.78||$85,994.64|| |
|3/3/2014||William Bernard O'connor||SVP||Sell||2,968||$30.31||$89,960.08|| |
|1/21/2014||Paul Michael Antinori||VP||Sell||37,883||$38.02||$1,440,311.66|| |
|1/15/2014||William Bernard O'connor||SVP||Sell||4,427||$39.15||$173,317.05|| |
|1/10/2014||William Bernard O'connor||SVP||Sell||72,384||$40.00||$2,895,360.00|| |
|1/7/2014||Clive Meanwell||CEO||Sell||27,929||$38.13||$1,064,932.77|| |
|1/3/2014||Clive Meanwell||CEO||Sell||57,516||$38.16||$2,194,810.56|| |
|12/9/2013||William Crouse||Director||Sell||12,500||$38.00||$475,000.00|| |
|12/5/2013||Glenn Sblendorio||CFO||Sell||8,516||$38.50||$327,866.00|| |
|12/2/2013||Clive Meanwell||CEO||Sell||10,000||$36.58||$365,800.00|| |
|11/26/2013||Clive Meanwell||CEO||Sell||135,000||$36.70||$4,954,500.00|| |
|10/23/2013||William Bernard O'connor||SVP||Sell||6,354||$35.00||$222,390.00|| |
|9/13/2013||Paul Michael Antinori||VP||Sell||73,500||$34.50||$2,535,750.00|| |
|9/3/2013||Clive Meanwell||CEO||Sell||7,500||$31.85||$238,875.00|| |
|8/1/2013||Clive Meanwell||CEO||Sell||7,500||$31.26||$234,450.00|| |
|7/8/2013||Paul Michael Antinori||VP||Sell||36,000||$33.00||$1,188,000.00|| |
|7/1/2013||Clive Meanwell||CEO||Sell||7,500||$31.25||$234,375.00|| |
|6/11/2013||Paul Michael Antinori||VP||Sell||109,973||$33.29||$3,661,001.17|| |
|5/29/2013||Armin M Kessler||Director||Sell||8,750||$33.05||$289,187.50|| |
|5/10/2013||Glenn Sblendorio||CFO||Sell||2,709||$37.00||$100,233.00|| |
|5/9/2013||Paul Michael Antinori||VP||Sell||35,000||$34.90||$1,221,500.00|| |
|5/9/2013||William Bernard O'connor||SVP||Sell||29,654||$35.00||$1,037,890.00|| |
Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
The Medicines Company (MDCO) Chart for Saturday, July, 22, 2017